Clinical Trial Update: A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipatasertib in combination with paclitaxel as neoadjuvant treatment for early-stage triple-negative breast cancer has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-09-20